Kezar Life Sciences has recently turned down an acquisition offer from Concentra Biosciences, which was priced at $1.10 per share. Additionally, Kezar has decided to put on hold their mid-stage study on Lupus Nephritis. This decision comes after careful consideration and evaluation by the company.